BioTime (BTX) Reports Q4 Loss of $0.58/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall St futures decline as US-Iran escalation rattles sentiment
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 3% as fresh military strikes threaten Hormuz shipments
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- The real reason Meta shares are surging has nothing to do with its new AI model
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
BioTime Reports Fourth Quarter and Fiscal 2017 Results
March 15, 2018 4:06 PM EDTRenevia® CE Mark application submitted for European approval OpRegen® receives DSMB approval to proceed to cohort 4 OpRegen® cohort 4 will include better vision patients and an array of additional functional assessments
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.
2017 was a successful year for BioTime, capped by our recent European CE Mark submission of Renevia® and... More
